Oncotarget

• 

  Publication Venue For

  • Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma..  13:1165. 2022
  • Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma..  13:576-582. 2022
  • P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses.  12:2252-2265. 2021
  • Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study..  12:1230-1242. 2021
  • Unexpected zinc dependency of ferroptosis - What is in a name?.  12:1126-1127. 2021
  • Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors..  12:1-3. 2021
  • Diffusion-weighted MR imaging histogram analysis in HIV positive and negative patients with primary central nervous system lymphoma as a predictor of outcome and tumor proliferation..  11:4093-4103. 2020
  • Ferroptosis of epithelial ovarian cancer: genetic determinants and therapeutic potential.  11:3562-3570. 2020
  • A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer.  11:3105-3117. 2020
  • Efficacy of osimertinib against EGFRvIII+ glioblastoma..  11:2074-2082. 2020
  • TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades..  11:1961-1970. 2020
  • A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer..  11:1334-1343. 2020
  • Correction: Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort..  11:758. 2020
  • Erratum: Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort (Oncotarget (2019) 10 (4857-4867) DOI: 10.18632/oncotarget.27108).  11:758. 2020
  • Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation (Oncotarget (2019) 10 (1874-1886) DOI: 10.18632/oncotarget.26740).  10:6045-6046. 2019
  • Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.  10:5671-5679. 2019
  • Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort..  10:4857-4867. 2019
  • Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma..  10:4546-4555. 2019
  • Integrating germline and somatic genomic analysis to probe etiological mechanism in malignant glioma..  10:3086-3087. 2019
  • ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation..  10:1874-1886. 2019
  • Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells..  10:1056-1069. 2019
  • UDP-α-D-glucose 6-dehydrogenase: A promising target for glioblastoma.  10:1542-1543. 2019
  • Intermediate phenotypes underlying osteosarcoma risk..  9:37345-37346. 2018
  • UBE2N plays a pivotal role in maintaining melanoma malignancy..  9:37347-37348. 2018
  • T-cell exhaustion in glioblastoma..  9:35287-35288. 2018
  • Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation..  9:33804-33817. 2018
  • Chromatin-associated APC regulates gene expression in collaboration with canonical WNT signaling and AP-1..  9:31214-31230. 2018
  • N6-methyladenosine contributes to cellular phenotype in a genetically-defined model of breast cancer progression..  9:31231-31243. 2018
  • Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality..  9:16099-16109. 2018
  • The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection..  9:7844-7858. 2018
  • Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts..  9:3459-3482. 2018
  • An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.  9:16213-16219. 2018
  • Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.  9:346-360. 2018
  • Cell surface GRP78 promotes tumor cell histone acetylation through metabolic reprogramming: a mechanism which modulates the Warburg effect..  8:107947-107963. 2017
  • Differential response to exercise in claudin-low breast cancer..  8:100989-101004. 2017
  • CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease..  8:100421-100432. 2017
  • Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk..  8:94900-94909. 2017
  • Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy..  8:96496-96505. 2017
  • The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells..  8:91914-91927. 2017
  • Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides..  8:77567-77585. 2017
  • Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors..  8:76644-76655. 2017
  • Genetic variants of PDGF signaling pathway genes predict cutaneous melanoma survival..  8:74595-74606. 2017
  • Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies..  8:73419-73432. 2017
  • Leptomeningeal disease: current diagnostic and therapeutic strategies..  8:73312-73328. 2017
  • Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci..  8:64670-64684. 2017
  • ROS-independent Nrf2 activation in prostate cancer..  8:67506-67518. 2017
  • Racial differences in prostate inflammation: results from the REDUCE study..  8:71393-71399. 2017
  • Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. 2017
  • ROS-independent Nrf2 activation in prostate cancer. 2017
  • A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer..  8:41474-41486. 2017
  • Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. 2017
  • Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.  8:25848-25863. 2017
  • Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies..  8:25848-25863. 2017
  • Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations..  8:24362-24371. 2017
  • Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging..  8:24213-24223. 2017
  • MDM4 genetic variants and risk of gastric cancer in an Eastern Chinese population..  8:19547-19555. 2017
  • Is there a dose-dependent effect of genetic susceptibility loci for gastric cancer on prognosis of the patients?.  8:18435-18443. 2017
  • Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma..  8:17586-17592. 2017
  • A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors..  8:16690-16703. 2017
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity..  8:10425-10436. 2017
  • Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation.  8:3826-3839. 2017
  • Comparison between proton boron fusion therapy (PBFT) and boron neutron capture therapy (BNCT): A monte carlo study.  8:39774-39781. 2017
  • Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.  8:42438-42454. 2017
  • Does uneven geographic distribution of urologists effect bladder and prostate cancers mortality? National health insurance data in Korea from 2007-2011.  8:65292-65301. 2017
  • Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma.  8:32201-32211. 2017
  • Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.  8:15912-15923. 2017
  • Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.  8:96496-96505. 2017
  • Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy.  8:104552-104559. 2017
  • New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate..  8:1007-1022. 2017
  • Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.  8:87044-87053. 2017
  • The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.  8:82661-82673. 2017
  • Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface..  7:84030-84042. 2016
  • Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia..  7:84214-84227. 2016
  • Associations of genotypes and haplotypes of IL-17 with risk of gastric cancer in an eastern Chinese population..  7:82384-82395. 2016
  • Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma..  7:81281-81291. 2016
  • Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma..  7:80599-80611. 2016
  • Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models..  7:79828-79841. 2016
  • Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors..  7:76565-76576. 2016
  • Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia..  7:72733-72745. 2016
  • Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration..  7:72381-72394. 2016
  • Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer..  7:69097-69110. 2016
  • Carcinogen 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis is accelerated in Smad3 heterozygous mice compared to Smad3 wild type mice..  7:64878-64885. 2016
  • Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood..  7:62898-62911. 2016
  • Genetic variants of genes in the Notch signaling pathway predict overall survival of non-small cell lung cancer patients in the PLCO study..  7:61716-61727. 2016
  • Potential implications of Apolipoprotein E in early brain injury after experimental subarachnoid hemorrhage: Involvement in the modulation of blood-brain barrier integrity..  7:56030-56044. 2016
  • Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149..  7:55721-55731. 2016
  • Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer..  7:50507-50521. 2016
  • Associations between smoking behavior-related alleles and the risk of melanoma..  7:47366-47375. 2016
  • Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma..  7:47794-47807. 2016
  • Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer..  7:47620-47636. 2016
  • Racial differences in prostate inflammation: results from the REDUCE study. 2016
  • Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer..  7:42385-42392. 2016
  • Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis..  7:38845-38856. 2016
  • A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer..  7:34472-34479. 2016
  • FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms..  7:34371-34383. 2016
  • Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy..  7:35015-35025. 2016
  • Unexpected positive control of NFκB and miR-155 by DGKα and ζ ensures effector and memory CD8+ T cell differentiation..  7:33744-33764. 2016
  • Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population..  7:28112-28123. 2016
  • PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction.  7:28218-28234. 2016
  • Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer..  7:25291-25303. 2016
  • Pre-miRNA variants as predictors of clinical outcome in patients with squamous cell carcinomas of the nonoropharynx..  7:26444-26453. 2016
  • Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer..  7:24088-24096. 2016
  • High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid..  7:21631-21643. 2016
  • Key roles of necroptotic factors in promoting tumor growth..  7:22219-22233. 2016
  • MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer..  7:20381-20394. 2016
  • Safety of two-year caloric restriction in non-obese healthy individuals..  7:19124-19133. 2016
  • The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer..  7:20293-20304. 2016
  • Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker..  7:18036-18049. 2016
  • Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population..  7:15930-15936. 2016
  • Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation..  7:16338-16348. 2016
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer..  7:13587-13598. 2016
  • Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia..  7:14659-14672. 2016
  • NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition..  7:12386-12392. 2016
  • Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty..  7:11899-11912. 2016
  • PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population..  7:9420-9428. 2016
  • A targeted genetic association study of epithelial ovarian cancer susceptibility..  7:7381-7389. 2016
  • Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer..  7:6353-6368. 2016
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)..  7:6984-6993. 2016
  • Angiomirs expression profiling in diffuse large B-Cell lymphoma..  7:4806-4816. 2016
  • The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia..  7:2721-2733. 2016
  • Endosome and INPP4B..  7:5-6. 2016
  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma..  7:2401-2416. 2016
  • Genetic variant of PRKAA1 and gastric cancer risk in an eastern Chinese population..  6:42661-42666. 2015
  • Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk..  6:42468-42477. 2015
  • Prevalence of deleterious ATM germline mutations in gastric cancer patients..  6:40953-40958. 2015
  • The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion..  6:41350-41359. 2015
  • Identification of CD146 as a marker enriched for tumor-propagating capacity reveals targetable pathways in primary human sarcoma..  6:40283-40294. 2015
  • MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management..  6:38591-38616. 2015
  • microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu)..  6:38705-38718. 2015
  • Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens..  6:38372-38380. 2015
  • A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer..  6:34745-34757. 2015
  • LGR5 is associated with tumor aggressiveness in papillary thyroid cancer..  6:34549-34560. 2015
  • Caspase 3 in dying tumor cells mediates post-irradiation angiogenesis..  6:32353-32367. 2015
  • IL-11 in multiple sclerosis..  6:32297-32298. 2015
  • Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration..  6:33769-33780. 2015
  • The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis..  6:33358-33368. 2015
  • Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin..  6:25061-25073. 2015
  • TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas..  6:24871-24883. 2015
  • Hyperinflammation, T cells, and endotoxemia..  6:23040-23041. 2015
  • Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells..  6:23959-23986. 2015
  • Perifosine as a potential novel anti-telomerase therapy..  6:21816-21826. 2015
  • Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma..  6:23157-23180. 2015
  • BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine..  6:19445-19455. 2015
  • Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival..  6:18653-18663. 2015
  • MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma..  6:18374-18388. 2015
  • Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies..  6:14656-14668. 2015
  • Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries..  6:14720. 2015
  • Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?.  6:13933-13945. 2015
  • Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone..  6:11357-11368. 2015
  • TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome..  6:7727-7740. 2015
  • Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries..  6:5615-5633. 2015
  • Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma..  6:5597-5614. 2015
  • Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth..  6:4266-4273. 2015
  • Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A..  6:2164-2179. 2015
  • Detecting cell-in-cell structures in human tumor samples by E-cadherin/CD68/CD45 triple staining.  6:20278-20287. 2015
  • A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly..  5:11813-11826. 2014
  • A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization..  5:12218-12232. 2014
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors..  5:9033-9038. 2014
  • A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors..  5:8161-8172. 2014
  • The NF1 gene revisited - from bench to bedside..  5:5873-5892. 2014
  • Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance..  5:3770-3784. 2014
  • Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma..  5:2635-2647. 2014
  • Caspase-8-mediated PAR-4 cleavage is required for TNFα-induced apoptosis..  5:2988-2998. 2014
  • Molecular pathways and therapeutic targets in lung cancer..  5:1392-1433. 2014
  • Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas..  5:1515-1525. 2014
  • The genetic landscape of anaplastic astrocytoma..  5:1452-1457. 2014
  • Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer..  5:1062-1070. 2014
  • KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation..  4:2144-2153. 2013
  • Exomic sequencing of four rare central nervous system tumor types..  4:572-583. 2013
  • Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans..  3:1428-1438. 2012
  • Mutant IDH1 is required for IDH1 mutated tumor cell growth..  3:774-782. 2012
  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas..  3:709-722. 2012
  • Double agents in the war on cancer: leukocytes govern ovarian cancer progression..  3:226-227. 2012
  • Toll-like receptor 2: Therapeutic target for gastric carcinogenesis.  3:1260-1261. 2012
  • CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells..  1:329-338. 2010
  • Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes..  1:265-277. 2010